Related Experiment Video

Updated: Jun 4, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

Regulating tumor cells to awaken T cell antitumor function and enhance melanoma immunotherapy

Weihan Zhang1, Shijun Yuan1, Zipeng Zhang2

  • 1Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.

Biomaterials
|December 22, 2024
PubMed

Insights

This study developed pH-responsive nanoparticles (NL/PLDs) to counteract tumor-induced T cell dysfunction. These nanoparticles enhance anti-tumor immunity and show potential for improving cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Nanotechnology
  • Biochemistry

Background:

  • Tumor cells create an immunosuppressive microenvironment (TIME) that impairs T cell function, leading to immune escape and cancer progression.
  • Counteracting tumor-induced T cell dysfunction is crucial for effective cancer immunotherapy.

Purpose of the Study:

  • To develop novel pH-responsive lipid nanoparticles (NL/PLDs) co-loaded with PCSK9 shRNA, lonidamine (LND), and low-dose doxorubicin (DOX).
  • To evaluate the ability of NL/PLDs to restore T cell function and enhance anti-tumor immunity.

Main Methods:

  • Preparation of pH-responsive lipid nanoparticles (NL/PLDs) co-delivering PCSK9 shRNA, LND, and DOX.
  • Assessment of NL/PLDs' effects on tumor immunogenicity, MHC-I expression, and lactic acid suppression in a melanoma mouse model.
  • Evaluation of combination therapy with NL/PLDs and anti-PD-1 (aPD-1) in vivo.

Main Results:

  • NL/PLDs effectively reversed T cell dysfunction by promoting T cell activation, recognition, and killing.
  • Treatment with NL/PLDs significantly reduced the immunosuppressive tumor microenvironment (TIME) and enhanced CD8+ T cell-mediated anti-tumor immunity.
  • Combination therapy of NL/PLDs with aPD-1 exhibited potent anti-tumor effects and improved immunotherapeutic efficacy.

Conclusions:

  • NL/PLDs represent a promising strategy for overcoming tumor-induced T cell suppression and enhancing anti-tumor immunity.
  • This approach offers new insights into regulating tumor immunosuppressive signals for improved clinical cancer treatment.
  • The developed nanoparticles show significant potential for enhancing the efficacy of current immunotherapies.
Keywords:
ImmunotherapyLactic acidMHC-ⅠPCSK9T cell dysfunction

More Related Videos

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

9.8K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

288

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
844
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K